Hostname: page-component-848d4c4894-xm8r8 Total loading time: 0 Render date: 2024-07-07T15:25:34.909Z Has data issue: false hasContentIssue false

Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses

Published online by Cambridge University Press:  16 April 2020

D.W. Stewart
Affiliation:
Department of General Psychiatry, NHS/Ravenscraig Hospital, Greenock, Scotland
M.S. Turner
Affiliation:
Department of General Psychiatry, NHS/The Larkfield Centre, Glasgow, Scotland

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

In schizophrenia, the objectives of long-term maintenance therapy are to achieve continuous relief from psychotic symptoms, to prevent relapse, to optimize patient functioning and improve quality of life. It is now generally accepted that atypical antipsychotic agents are more effective than conventional agents in achieving these goals over the short term. In order to define the role of atypical antipsychotics as maintenance treatment for schizophrenia, studies published between January 1994 and September 2006 that evaluated the long-term efficacy (>1 year) of atypical antipsychotics were identified and reviewed from literature searches using MEDLINE and EMBASE. The primary research parameters were ‘atypical’, ‘antipsychotic’, ‘schizophrenia’, ‘relapse’, ‘long-term’, ‘maintenance’ and ‘efficacy’. Aspects of safety were also considered for these agents. Results from these long-term studies consistently demonstrated that atypical antipsychotics have substantial advantages over oral conventional antipsychotics as proven by fewer relapses, more effective symptom control and a lower incidence of movement disorders, although some atypical agents were associated with a higher incidence of weight gain.

However, due to issues of compliance, the clinical advantage of oral atypical antipsychotics has often been limited. As such, the use of long-acting preparations of atypical antipsychotics, which provide consistent and sustained drug coverage, warrants further investigation for the successful long-term management of patients with schizophrenia.

Type
Poster Session 1: Antipsychotic Medications
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.